Nanobiotix (NANO) Corporate presentation summary

Strategic partnerships and market opportunity

• Entered a $2.6B+ license agreement with Johnson & Johnson for NBTXR3, including royalties and milestone payments, targeting major oncology markets.

• Focused on large, untapped oncology segments, especially head and neck and lung cancers, with over 100,000 addressable patients in the US and EU5 and a $10B market potential.

• Ongoing global Phase 3 (NANORAY-312) in head and neck cancer and Phase 2 (CONVERGE) in lung cancer, with multiple additional indications in development.

• Building a diversified pipeline with opportunities for collaborations and licensing, leveraging partnerships with top-tier pharma and research institutions.

Product innovation and clinical differentiation

• NBTXR3 is a first-in-class radioenhancer using hafnium oxide nanoparticles to amplify radiotherapy effects, selectively increasing tumor cell death while minimizing healthy tissue damage.

• Demonstrated significant clinical benefit in Phase 2/3 trials, including doubling pathological complete response rates in soft tissue sarcoma and strong efficacy in head and neck and lung cancers.

• Designed for single intratumoral administration, easy integration into existing radiotherapy workflows, and broad applicability across solid tumors.

• Early data in NSCLC shows 71% objective response rate and 100% disease control rate post-chemoradiotherapy.

Financial outlook and sustainability

• Cash position of €52.8M as of December 31, 2025, with a runway into early 2028, supported by milestone payments and royalty streams.

• Over $200M in medium-term milestones expected in the next 2-3 years from ongoing programs, with potential for $2.3B+ in long-term milestones.

• Dual-listed on Euronext Paris and Nasdaq, with 48.5M shares outstanding and additional funding from loans and royalty financing.